ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1410	National Cancer Institute	Html	en	Endometrial Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing endometrial cancer and about research aimed at the prevention of this disease.	Surgical Adjuvant Breast 0.47836 Obstet Gynecol 0.483376 World Cancer Research 0.452806 endometrial carcinoma 0.52954 Engl J Med 0.456388 American Cancer Society 0.497798 Br J Cancer 0.455416 case-control study 0.441437 Int J Cancer 0.478131 early-stage breast cancer 0.461817 intentional weight loss 0.529248 breast cancer treatment 0.473891 breast cancer patients 0.472714 body mass index 0.470175 endometrial cases 0.529694 Cancer Causes Control 0.452081 Natl Cancer Inst 0.529481 lower endometrial cancer 0.563354 postmenopausal endometrial cancer 0.554715 modifiable risk factor 0.44186 endometrial cancer 0.948645 invasive breast cancer 0.472622 Cancer Treat Rep 0.454232 et al. 0.498732	early breast cancer 0.472532 tamoxifen-treated breast cancer 0.462067 nonpolyposis colorectal cancer 0.457467 endometrial cancer cases 0.601622 polycystic ovarian syndrome 0.445837 Cancer Epidemiol Biomarkers 0.47249 endometrial cancer risk 0.82277 Cancer Facts 0.44862 PUBMED Abstract 0.515106 Nutr Cancer 0.444116 widespread endometrial cancer 0.555715 Epidemiol Biomarkers Prev 0.442397 endometrial cancer incidence 0.612962 Breast Cancer Prevention 0.475561 African American women 0.440785 invasive gynecologic cancer 0.464853 postmenopausal women 0.497969 Abstract 0.52778 breast cancer 0.526041 adjuvant tamoxifen 0.441172 physical activity 0.445711 Breast Cancer Study 0.467445 breast cancer incidence 0.479289 National Surgical Adjuvant 0.475167	CLICK HERE
1522	National Cancer Institute	Html	en	Childhood Brain Stem Glioma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood brain stem glioma.	PDQ Childhood Brain 0.262624 cancer treatment 0.317391 new cancer cells 0.250632 brain stem glioma 0.990842 metastatic brain tumors 0.262145 type 0.250835 PDQ cancer information 0.305049 clinical trial search 0.257718 brain tumors 0.389165 children 0.259907 clinical trials 0.541127 health care providers 0.255221 Pediatric Treatment Editorial 0.256101 cancer information summary 0.282392 clinical trial 0.361183 patients 0.252235 NCI PDQ cancer 0.25809 radiation therapy 0.3037 Treatment Editorial Board 0.258484 intrinsic pontine glioma 0.314731 focal childhood brain 0.250848 late effects 0.256779 treatment 0.494086 focal glioma 0.286058 cancer cells 0.359639	brain stem gliomas 0.410944 primary brain tumors 0.262357 PDQ Pediatric Treatment 0.253085 signs 0.25352 Benign brain tumors 0.261631 treatment clinical trials 0.275821 National Cancer Institute 0.282821 following PDQ treatment 0.270231 effects cancer treatment 0.263814 new treatment 0.290537 childhood cancer information 0.253956 childhood brain tumors 0.305915 BRAF kinase 0.259925 treatment clinical trial 0.25851 PDQ summary 0.250138 Malignant brain tumors 0.261555 cancer clinical trials 0.275926 focal brain stem 0.331856 treatment options 0.261824 brain tissue 0.259205 cancer 0.498153 standard treatment 0.287654 BRAF kinase inhibitor 0.253173 childhood brain stem 0.659927	CLICK HERE
1545	National Cancer Institute	Html	en	Adult Hodgkin Lymphoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of adult Hodgkin lymphoma.	red blood cells 0.404993 cancer treatment 0.406441 body 0.406679 PDQ cancer information 0.415705 unfavorable Hodgkin lymphoma 0.403766 Non-Hodgkin Lymphoma Treatment 0.396504 clinical trial search 0.387461 pregnant women 0.365816 favorable Hodgkin lymphoma 0.403909 white blood cells 0.390827 favorable adult Hodgkin 0.379079 unfavorable adult Hodgkin 0.379392 clinical trials 0.634552 lymph nodes 0.463894 cancer information summary 0.39389 clinical trial 0.489293 stem cell transplant 0.415484 recurrent Hodgkin lymphoma 0.402776 adult hodgkin lymphoma 0.802336 patients 0.379207 blood cells 0.446195 weight loss 0.391968 NCI PDQ cancer 0.365284 radiation therapy 0.587067 Nodular sclerosing Hodgkin 0.384149	lymph node groups 0.460532 treatment 0.56475 night sweats 0.39371 Hodgkin Lymphoma Treatment 0.422215 cancer cells 0.401875 cellularity Hodgkin lymphoma 0.419706 swollen lymph nodes 0.429808 treatment clinical trials 0.386111 National Cancer Institute 0.39221 lymph vessels 0.383555 new treatment 0.393163 advanced hodgkin lymphoma 0.435901 Hodgkin lymphomas 0.368401 classical Hodgkin lymphoma 0.419308 bone marrow 0.427904 depletion Hodgkin lymphoma 0.419209 sedimentation rate 0.371778 hodgkin lymphoma 0.94955 cancer clinical trials 0.401646 stage 0.410094 Combination chemotherapy 0.415703 cancer 0.682215 information 0.416232 appropriate cancer treatment 0.37213	CLICK HERE
1621	National Cancer Institute	Html	en	Ewing Sarcoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of Ewing sarcoma.	cancer treatment 0.289749 malignant tumor cells 0.276208 soft tissue 0.253817 body 0.332426 type 0.219713 chemotherapy 0.237331 treatments 0.202586 PDQ cancer information 0.292839 clinical trial search 0.246556 extraosseous Ewing sarcoma 0.264218 Ewing sarcoma spreads 0.243807 clinical trials 0.704097 Pediatric Treatment Editorial 0.209616 nearby lymph nodes 0.208892 cancer information summary 0.25517 clinical trial 0.374839 recurrent Ewing sarcoma 0.335434 stage Ewing sarcoma 0.262403 patients 0.209976 Soft Tissue Sarcoma 0.20334 childhood Ewing sarcoma 0.227663 CAR T-cell therapy 0.238653 NCI PDQ cancer 0.207565 Ewing sarcoma family 0.264166 radiation therapy 0.525383	Treatment Editorial Board 0.214583 treatment 0.586815 Ewing sarcoma 0.925686 Ewing sarcoma cells 0.277555 NCI-supported cancer 0.206887 cancer cells 0.457951 metastatic Ewing sarcoma 0.365401 specific cancer cells 0.219988 patient 0.217481 treatment clinical trials 0.236708 National Cancer Institute 0.256904 initial treatment 0.212474 effects cancer treatment 0.221598 new treatment 0.271508 bone 0.246041 metastatic tumor 0.210193 bone marrow 0.235686 Ewing tumor 0.226375 cancer clinical trials 0.279951 stem cell rescue 0.32512 tumor 0.434783 High-dose chemotherapy 0.218893 cancer 0.820936 standard treatment 0.227171	CLICK HERE
1718	National Cancer Institute	Html	en	Pap and HPV Testing	A fact sheet that describes the Pap and HPV tests, possible results from those tests, and the link between HPV and cervical cancer.	Pap test results 0.318639 precancerous cervical lesions 0.292159 squamous cells 0.289348 high-risk HPV 0.671741 First-line HPV testing 0.290741 squamous cell abnormalities 0.296427 primary HPV screening 0.318981 cervical screening 0.408649 glandular cell abnormalities 0.323902 professional cervical cancer 0.287037 cervical cells 0.449089 Pap test 0.978312 HPV testing 0.403472 frequent cervical screening 0.280097 cell abnormalities 0.445026 HPV test 0.442688 negative HPV test 0.307642 cervical cancer screening 0.819575 positive HPV test 0.337496 cervical cancer 0.958343 HPV DNA test 0.30151 Pap cytology test 0.279358 early cervical cancers 0.308324 HPV infections 0.362202	HPV test results 0.327074 abnormal cells 0.314778 abnormal cervical cells 0.343301 precancerous cervical lesion 0.309268 HPV 0.765136 Pap test result 0.433853 different HPV tests 0.296834 cervical cell abnormalities 0.361261 cobas HPV test 0.304363 high-risk HPV types 0.661339 additional high-risk HPV 0.303577 new cervical cancers 0.27692 high-risk HPV type 0.405337 cervical cancer risk 0.324311 HPV cotesting 0.335213 liquid-based Pap cytology 0.286767 future cervical cancer 0.287194 abnormal Pap test 0.300522 HPV infection 0.371378 cells 0.464647 regular cervical screening 0.330087 Routine cervical screening 0.314661 Pap testing 0.293059 cell changes 0.293167	CLICK HERE
1935	National Cancer Institute	Html	es	Tratamiento del ependimoma infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del ependimoma infantil.	radiocirugía estereotáctica 0.685192 siguientes procedimientos 0.332065 efectos secundarios meses 0.562136 siguientes áreas 0.378745 huesos dorsales 0.375848 general recidiva 0.34956 efectos tardíos 0.729968 PDQ Efectos tardíos 0.453185 cabo irm 0.352274 líquido cefalorraquídeo 0.982409 punción espinal.Ampliar 0.373407 estudio clínico 0.337757 National Cancer Institute 0.329628	siguientes riesgos 0.321782 Instituto Nacional 0.357335 PDQ Tratamiento 0.392525 determinados cambios 0.326515 gen rela 0.670707 nuevos tipos 0.348217 siguientes factores 0.370167 sistema nervioso central 0.663463 Physician Data Query 0.423559 segura.ampliar craneotomía 0.353248 cuánto tumor 0.478632 siguientes sumarios 0.438618	CLICK HERE
3438	National Cancer Institute	Html	es	Exámenes de detección del cáncer de estómago (gástrico) (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de estómago (gástrico).	Offerhaus J 0.113586 Cancer Res Clin 0.264444 Cancer high-risk subjects 0.263357 mass screening 0.365942 Leung WK 0.124317 Kobayashi K 0.11932 American Cancer Society 0.823817 detección versus 0.189954 case-control study 0.112022 Tytgat GN 0.125733 CA Cancer 0.258236 Instituto Nacional 0.144846 PDQ Exámenes 0.215492 prospectively followed chinese 0.229607 Estados Unidos 0.202827 Yanaoka K 0.108053 biological agents 0.104643 Morson BC 0.118473 high risk 0.121936 repeated endoscopic screens 0.228776 Lancet Oncol 0.24929 mass screening program 0.337333 mass survey 0.121584 Gastrointestinal Tract 0.130066 Ma JL 0.109737	mass screening techniques 0.150063 Precancerous Lesions 0.123357 Barbara L 0.103989 Cancer Facts 0.263557 Pfeiffer R 0.11257 Costa Rica 0.0971337 detección darán 0.220411 Mathus-Vliegen EM 0.121366 Ubukata T 0.120185 National Cancer Institute 0.793771 Oka M 0.099234 gastric carcinoma 0.217462 Endoscopic screening during 0.138672 serum pepsinogen concentrations 0.241325 New York 0.185957 Clin Oncol 0.132653 Kitahara F 0.112823 Sherlock P 0.239085 X-ray screening seems 0.130764 serum pepsinogen 0.612986 using serum pepsinogen 0.482271 Sato T 0.127922 stomach cancer 0.944477 Wu MS 0.109301	CLICK HERE
3576	National Cancer Institute	Html	en	Cancer Prevention Research	NCI’s prevention research has a broad focus, from identifying environmental and lifestyle factors that influence cancer risk to studying the biology of how cancer develops and studying ways to disseminate prevention interventions.	potential preventive therapies 0.441911 cancer prevention trials 0.552513 Drug Development Program 0.440287 PREVENT Cancer Preclinical 0.524374 higher cancer rates 0.5328 public health imperative 0.449962 Tobacco Control Research 0.447635 tobacco control programs 0.463087 invasive cancer 0.460548 specific population groups 0.436493 behavioral risk factors 0.665388 cancer care 0.47747 NCI’s Division 0.485356 cervical cancer 0.456337 Reduce Cancer Health 0.518587 FDA-approved HPV vaccines—work 0.439068 NCI’s Center 0.488421 Cancer Epidemiology 0.455548 prevention-focused clinical studies 0.444916 cancer health disparities 0.673431 Cancer Control 0.456877 risk reduction 0.469434 cancer screening 0.48636 cancer prevention 0.875489	United States 0.669252 new cancer prevention 0.553181 annual cancer-related deaths 0.450355 Cancer Research 0.477162 studies 0.468685 HPV-associated cancer 0.458082 cancer researchers 0.479223 substantially increased risk 0.487266 prevention research efforts 0.4695 HPV vaccine trials 0.440028 NCI Community Oncology 0.488471 new preventive therapy 0.454621 cancer development 0.485138 people 0.446203 cancer prevention research 0.671334 cancer disparities 0.497724 physical activity 0.439301 bivalent HPV vaccine 0.436545 Cancer Prevention Clinical 0.54727 NCI Cohort Consortium 0.479534 cancer risk 0.971388 cancer 0.983944 cancer incidence 0.537166 genome-wide association studies 0.438797	CLICK HERE
3670	National Cancer Institute	Html	es	Estudio TAILORx indica que mujeres con riesgo bajo de recurrencia de cáncer de seno pueden abstenerse de quimioterapia	Resumen de resultados del estudio TAILORx indica que mujeres con cáncer de seno receptor de hormonas en estadio inicial tienen un riesgo bajo de recurrencia según una prueba de expresión de 21 genes.	Assigning Individualized Options 0.731016 NIC-Clinical Trials Group 0.677172 Therapy Evaluation Program 0.674291 quimioterapia adyuvante mejora 0.979078 doctor joseph sparano 0.667749 doctora jo anne 0.660047 llamada puntuación 0.615517 Estados Unidos 0.857653 NRG Oncology 0.56481	excelentes resultados 0.548811 cuáles mujeres 0.873744 Oncotype DX® 0.57646 invasivo enfermedad 0.55814 New England Journal 0.693093 Clinical Oncology 0.572538 Nueva Zelanda 0.530968 estudio tailorx 0.733998	CLICK HERE
15877	National Cancer Institute	Html	es	Antineoplastones (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre los antineoplastones como tratamiento para personas con cáncer.	corta duración 0.52325 suficientes antineoplastones 0.570315 Centro Nacional 0.534282 New Hampshire Avenue 0.523956 cabo ensayos 0.607081 Drug Administration 0.514884 antineoplastones a10 0.621411 NCI Best Case 0.546794 siguientes tipos 0.528576 PDQ Antineoplastones 0.580269 datos bibliográficos pubmed 0.525907 siguientes preguntas 0.515649 fase ii 0.701787 células tumorales animales 0.553458 National Cancer Institute 0.529942 siguientes riesgos 0.520138 seguro médico 0.513988	Instituto Nacional 0.710175 Salud Complementaria 0.553301 Visuals Online 0.517781 complementarias revisa 0.52541 Physician Data Query 0.604461 antineoplastones a2 0.575169 Estados Unidos 0.855832 corto plazo 0.520833 libre uso 0.517405 página manejo 0.516526 ¿El tratamiento 0.536286 Clínica Mayo 0.524069 ¿Los beneficios 0.515122 juntos cam 0.514422 Series Program 0.514906 medicina complementaria 0.99587	CLICK HERE